-

07:16:53 AM

CELC Stock News

CELC - Celcuity Inc

03/23/23 4:00 PM

Nasdaq : CELC

earningslow float

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025 Updated clinical data from the Phase 1b advanced breast cancer trial with gedatolisib was presented at

RHEA-AI

neutral

03/16/23 8:00 AM

Nasdaq : CELC

earningslow float

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market

RHEA-AI

neutral

03/15/23 7:35 PM

Nasdaq : CELC

conferencesclinical triallow float

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other

RHEA-AI

neutral

03/01/23 8:00 AM

Nasdaq : CELC

conferenceslow float

Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen's 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023.

RHEA-AI

neutral

02/16/23 8:00 AM

Nasdaq : CELC

clinical triallow float

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused

RHEA-AI

neutral

12/12/22 7:30 AM

Nasdaq : CELC

low float

Celcuity Closes $100 Million Private Placement

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses. The

RHEA-AI

neutral

12/09/22 8:40 AM

Nasdaq : CELC

clinical triallow float

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

RHEA-AI

neutral

12/07/22 4:00 PM

Nasdaq : CELC

clinical triallow float

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that

RHEA-AI

very positive

11/22/22 7:30 AM

Nasdaq : CELC

conferenceslow float

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast

RHEA-AI

very positive

11/10/22 4:30 PM

Nasdaq : CELC

conferenceslow float

Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity,

RHEA-AI

neutral

1 2 3 4 5 6 Next

CELC Data

IndustryMedical Laboratories
Websitecelcuity.com
Security nameCelcuity Inc
Issue typecs
SectorHealth Care and Social Assistance
Sic code8071
Employees39
Tags
- Commercial Services
- Miscellaneous Commercial Services
- Health Care and Social Assistance
- Medical Laboratories

About Celcuity Inc

Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN.